Company intelligence

KMDA

Kamada Ltd. · NASDAQ · Healthcare

Price$7.92-0.88% · −$0.07

Market cap456.94MEquity value

P / E20.8Trailing ratio

Volume106.62KLatest session

Market data

KMDA price chart

TradingView

Related signals

1 min delayed

Browse public KMDA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KMDADec 8, 2025+1.41% since signal

Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

Kamada discontinues Phase 3 trial for inhaled AAT due to limited efficacy. Shares down 5.51% following the trial discontinuation announcement. CEO emphasizes strong growth prospects despite trial outcome. Full-year 2025 revenue guidance remains between $178M to $182M. Kamada plans double-digit growth through commercial portfolio expansion.

View signal analysis

Research